Sir, Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
We thank Dan Călugăru and Mihai Călugăru for their insight into our publication; however, we disagree with several of the points they made.
There is no clear data showing the greater efficacy of switching to steroids versus aflibercept in cases of chronic DME refractory to bevacizumab/ranibizumab therapy (Table 1 ). In addition, steroids are known to cause complications such as elevated IOP as well as cataracts which is a limitation to their use particularly in phakic patients. The exact timing of this switch is particularly important because as suggested by the FAME study, chronic edema is estimated to begin 1.73 years post the start of edema. 1 Patients treated with steroids in the FAME study who had edema o3 years failed to show anatomic or visual gains compared with the sham group. Only patients who had edema 43 years responded significantly. If we were to consider the definition suggested, patients are expected to have received at least 19 prior injections before steroids would be a valid option. In the study by Rahimy et al 2 patients had a previous median of 13 injections which would fall within the predicted margin of non-chronic edema. Therefore, it is Although it is tempting to class all anti-VEGFs together and that they are all fairly interchangeable, recent data from protocol T has demonstrated significant anatomical differences between aflibercept, ranibizumab, and bevacizumab during the first year especially for patients with baseline VA o20/40 (6/12). 3 The exact reason for this difference although speculative cannot be disregarded (CFT o250 microns in 70% of cases treated with aflibercept compared with 60% for ranibizumab and 50% for bevacizumab). It also highlights the anatomic effectiveness of aflibercept in resolving edema, especially in patients with high volumes of residual fluid. 4 With regards to switching, the study by Rahimy et al showed that 25% of patients achieved dryness, whereas 56% showed improvement. 2 Wood et al showed that 80% of eyes showed some improvement in anatomy. 5 This anatomic improvement in a significant percentage of patients is worth exploring before switching to steroids, which has been shown in the switch studies to cause increased IOP in~20-25% of cases with many patients requiring re-treatments (Table 1) .
Finally, switching in DME has not been extensively studied; AMD has over 40 publications that have tackled switching to aflibercept compared with only 3 in DME. [5] [6] [7] This issue warrants more studies and more data before reaching a definitive conclusion regarding the efficacy and timing of switching. However, it remains a valid first option in non-responsive cases before steroid switch. In their interesting article, Scholz et al 1 compare 2 treatments for chronic central serous chorioretinopathy (cCSC) on the basis of changes in central retinal thickness (CRT) and resolution of subretinal fluid (SRF) at 6 weeks after treatment. The authors conclude that significantly more patients showed a treatment response to subthreshold micropulse laser (SML) treatment and that SML leads to a greater decrease in CRT in comparison with half-dose photodynamic therapy (PDT). There was no statistically significant difference in complete SRF resolution and bestcorrected visual acuity between the 2 groups after a posttreatment follow-up period of 6 weeks. In cCSC, a complete SRF resolution may be an important anatomical outcome parameter of treatment because such a resolution reconstitutes the normal relationship between photoreceptors and retinal pigment epithelium, and persistent SRF appears to be an important risk factor for long-term vision loss. 2 In the study by Scholz et al, the percentage of patients who showed complete resolution of SRF on OCT in both the SML and the half-dose PDT group was remarkably low as compared with previous large retrospective studies, which describe complete resolution in 41-100% of cCSC cases. 3, 4 The authors indicate that this could have been caused by a relatively long disease duration in the included patients. Indeed, the clinical definition of cCSC and treatment inclusion criteria for cCSC is variable and subject to debate, and may influence the likelihood of treatment success. 3 The relatively short follow-up period of 6 weeks to evaluate treatment success may have also influenced the rate of SRF resolution. 4 Also, abnormalities on indocyanine green angiography (ICGA) in cCSC are often more extensive than those on fluorescein angiography, indicating primary choroidal dysfunction, and may therefore favour ICGA-based treatment to increase the likelihood of complete SRF resolution.
A wide variety of treatments has been advocated for cCSC, underlining the controversy surrounding cCSC therapy. 5 On basis of the available retrospective evidence, SML and PDT appear the most promising candidate treatments. 5 As indicated by the authors, large prospective multicenter randomized controlled treatment trials are pivotal to establish the optimal treatment modality for cCSC. Treatment with both 577 nm and 810 nm SML has been used in cCSC and no clear preference can be advocated based on the available literature.
In collaboration with the authors, we are currently conducting a prospective multicenter randomized controlled treatment trial (the PLACE trial) comparing halfdose PDT with 810 nm SML in cCSC. 6 In this trial, both anatomical outcome parameters such as a complete resolution of SRF and functional outcome parameters such as visual acuity, microperimetry, and Visual Functioning Questionnaire-25 score are taken into account, within a follow-up period of up to 8 months. 6 The results of these studies may hopefully lead to an evidence-based bestpractice guideline for the treatment of cCSC.
